Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Adicet Bio, Inc.

Get SEC filing alerts via email and in your feed for Adicet Bio, Inc.

ACET

Adicet Bio, Inc.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical-stage biotechnology company developing allogeneic "off-the-shelf" gamma delta T cell therapies engineered with chimeric antigen receptors (CARs) for autoimmune diseases and cancer. Its pipeline includes product candidates targeting B cell-mediated autoimmune disorders and CD70+ solid tumors. Adicet’s proprietary platform enables scalable manufacturing from unrelated donors, offering potential advantages in safety, tissue targeting, and cost-efficiency over autologous and other cell therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Adicet Bio, Inc.

1
1
Adicet Bio, Inc. Adicet Bio Reports $20.2 Million Net Loss in Q1 2026, Reduces Operating Expenses

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Adicet Bio, Inc. Adicet Bio Reports $116.8 Million Net Loss for 2025, Focuses on Clinical Trials

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Adicet Bio, Inc. Adicet Bio Reports $26.9 Million Net Loss in Q3 2025, Progresses with Clinical Trials

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Adicet Bio, Inc. Adicet Bio Reports $31.2 Million Net Loss in Q2 2025, Focuses on Lead Candidate ADI-001

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Adicet Bio, Inc. Adicet Bio Reports $28.2 Million Net Loss in Q1 2025, Seeks Additional Financing

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Adicet Bio, Inc. Adicet Bio Reports $117.1 Million Net Loss for 2024, FDA Clears IND Applications for ADI-001 and ADI-270

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Adicet Bio, Inc. Adicet Bio Reports Financial Results, Net Loss Decrease, and Shift in Focus to ADI-001 for Autoimmune Diseases

Via official filing (AI summary) | over 1 year ago | 0 comments